학술논문
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
Document Type
Article
Author
Kawashima, Yosuke; Fukuhara, Tatsuro; Saito, Haruhiro; Furuya, Naoki; Watanabe, Kana; Sugawara, Shunichi; Iwasawa, Shunichiro; Tsunezuka, Yoshio; Yamaguchi, Ou; Okada, Morihito; Yoshimori, Kozo; Nakachi, Ichiro; Seike, Masahiro; Azuma, Koichi; Kurimoto, Futoshi; Tsubata, Yukari; Fujita, Yuka; Nagashima, Hiromi; Asai, Gyo; Watanabe, Satoshi; Miyazaki, Masaki; Hagiwara, Koichi; Nukiwa, Toshihiro; Morita, Satoshi; Kobayashi, Kunihiko; Maemondo, Makoto
Source
In The Lancet Respiratory Medicine January 2022 10(1):72-82
Subject
Language
ISSN
2213-2600